incidence of pancreatitis with glp-1 New data links agonists for weight loss higher risk for pancreatitis, GI events Dose-dependent pancreatitis risk associated with

While most are mild and temporary, its crucial to know which symptoms might need medical attention to ensure your treatment stays safe and effective

Neuropharmacology 86, 2230

The limited familiarity of primary care physicians with incretin-based therapies can significantly impact accessibility to GLP-1 RAs, given that most people with type 2 diabetes are treated by primary care physicians rather than diabetologists or endocrinologists

A comparative analysis found that non-diabetic patients with obesity on tirzepatide had a 64% lower risk of developing new-onset gastroparesis compared to those on semaglutide

Those who took them showed less RA disease activity and lower levels of systemic inflammatory markers such as C-reactive protein compared with others

Long-term results of one anastomosis gastric bypass: a single center experience with a minimum follow-up of 10 years